**Supplementary Table S1.** Adverse events considered possibly, probably, or definitely related to cediranib (intention-to-treat population, *n* = 34)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Adverse event, *n* (%)** | **Grade** | | | | |
| **1** | **2** | **3** | **4** | **Any** |
| Diarrhea | 16 (47) | 3 (9) | 4 (12) | 0 | 23 (68) |
| Other | 14 (41) | 4 (12) | 0 | 0 | 18 (53) |
| Fatigue | 11 (32) | 3 (9) | 1 (3) | 0 | 15 (44) |
| Vomiting | 7 (21) | 3 (9) | 1 (3) | 0 | 11 (32) |
| Nausea | 9 (26) | 1 (3) | 0 | 0 | 10 (29) |
| Hypertension | 1 (3) | 5 (15) | 2 (6) | 0 | 8 (24) |
| Anemia | 1 (3) | 2 (6) | 3 (9) | 0 | 6 (18) |
| Generalized muscle weakness | 2 (6) | 3 (9) | 1 (3) | 0 | 6 (18) |
| Anorexia | 3 (9) | 2 (6) | 0 | 0 | 5 (15) |
| QTc interval prolonged | 3 (9) | 2 (6) | 0 | 0 | 5 (15) |
| Hoarseness | 5 (15) | 0 | 0 | 0 | 5 (15) |
| Proteinuria | 3 (9) | 2 (6) | 0 | 0 | 5 (15) |
| Mucositis oral | 2 (6) | 2 (6) | 0 | 0 | 4 (12) |
| Dysgeusia | 3 (9) | 0 | 0 | 0 | 3 (9) |
| Headache | 3 (9) | 0 | 0 | 0 | 3 (9) |
| Weight loss | 2 (6) | 1 (3) | 0 | 0 | 3 (9) |
| Alanine aminotransferase increased | 1 (3) | 0 | 1 (3) | 0 | 2 (6) |
| Alkaline phosphatase increased | 1 (3) | 1 (3) | 0 | 0 | 2 (6) |
| Blood bilirubin increased | 1 (3) | 1 (3) | 0 | 0 | 2 (6) |
| Creatinine increased | 2 (6) | 0 | 0 | 0 | 2 (6) |
| Dry mouth | 2 (6) | 0 | 0 | 0 | 2 (6) |
| Epistaxis | 2 (6) | 0 | 0 | 0 | 2 (6) |
| Hypothyroidism | 1 (3) | 1 (3) | 0 | 0 | 2 (6) |
| Myalgia | 1 (3) | 0 | 1 (3) | 0 | 2 (6) |
| Neutrophil count decreased | 2 (6) | 0 | 0 | 0 | 2 (6) |
| Platelet count decreased | 1 (3) | 1 (3) | 0 | 0 | 2 (6) |
| White blood cell decreased | 1 (3) | 1 (3) | 0 | 0 | 2 (6) |
| Abdominal pain | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Aphonia | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Aspartate aminotransferase increased | 0 | 0 | 1 (3) | 0 | 1 (3) |
| Bloating | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Bruising | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Constipation | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Dehydration | 0 | 0 | 1 (3) | 0 | 1 (3) |
| Dry skin | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Dyspepsia | 0 | 1 (3) | 0 | 0 | 1 (3) |
| Ejection fraction decreased | 0 | 0 | 1 (3) | 0 | 1 (3) |
| Flushing | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Gamma-glutamyltransferase increased | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Gingival pain | 0 | 1 (3) | 0 | 0 | 1 (3) |
| Hematuria | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Insomnia | 0 | 1 (3) | 0 | 0 | 1 (3) |
| Palmar-plantar erythrodysesthesia syndrome | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Palpitations | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Rash acneiform | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Rectal hemorrhage | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Sinus tachycardia | 0 | 1 (3) | 0 | 0 | 1 (3) |
| Skin hyperpigmentation | 1 (3) | 0 | 0 | 0 | 1 (3) |
| Thromboembolic event | 0 | 0 | 1 (3) | 0 | 1 (3) |
| Upper respiratory infection | 1 (3) | 0 | 0 | 0 | 1 (3) |